文献速递眼底病与葡萄膜炎

抗血管内皮生长因子治疗与新生血管性年龄相关性黄斑变性中的萎缩:系统文献综述与专家意见

Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion.
PubMed 文献 · Ophthalmology · 2019-11-22

该系统综述检索了PubMed近5年文献,纳入29项研究,总结接受抗VEGF治疗的新生血管性年龄相关性黄斑变性(nAMD)患者的萎缩发生率、危险因素及萎缩相关视力结局。所有研究均证实萎缩发生,纵向数据显示萎缩发生率随时间增加;萎缩危险因素包括对侧眼萎缩、网状假性玻璃膜疣、注射次数增加和3型病灶。专家意见强调充分治疗渗出性MNV仍是优化视力结局的最佳选择。

要点

  • 所有纳入研究均证实接受抗VEGF治疗的MNV眼会发生萎缩,纵向数据显示萎缩发生率随时间增加。
  • 与萎缩相关的关键危险因素或表型包括对侧眼萎缩、网状假性玻璃膜疣、注射次数增加和3型病灶。
  • 黄斑中心凹萎缩与视力丧失相关;充分治疗渗出性MNV仍是优化nAMD患者视力结局的最佳选择。

核心结论

  • 所有研究均显示在接受抗VEGF治疗的MNV背景下发生萎缩,但尚不清楚抗VEGF治疗是导致萎缩的原因还是仅与萎缩发生相关。

研究设计与样本

  • 系统文献综述:检索PubMed 2014年1月1日至2019年1月10日发表的文献,纳入报告接受抗VEGF治疗的年龄相关性黄斑变性患者萎缩结局的研究,排除综述、回顾性研究、病例报告、临床前研究、患病率数据报告和非英文研究。
  • 共识别145项研究,最终纳入29篇出版物,队列范围从8只眼到1185只眼。

主要发现

  • 所有研究均证实萎缩发生;当有纵向数据时,显示萎缩发生率随时间增加。
  • 与萎缩相关的关键危险因素或表型为对侧眼萎缩、网状假性玻璃膜疣、注射次数增加和3型病灶。
  • 黄斑中心凹萎缩伴有视力丧失。

关键数值与推荐

  • 各研究用于评估萎缩的成像方法不同。
  • 纳入研究并非设计或检验效能不足以将萎缩作为主要结局进行评估。

临床怎么用

  • 尽管表型和危险因素可能有助于识别萎缩发生风险较高的患者,但充分治疗渗出性MNV仍是优化nAMD患者视力结局的最佳选择。
  • 尤其考虑到真实世界中治疗不足带来的视力丧失风险,应重视充分治疗渗出性MNV。

局限性

  • 尚不清楚抗VEGF治疗是导致萎缩的原因还是仅与萎缩发生相关。
  • 纳入研究并非设计或检验效能不足以将萎缩作为主要结局进行评估。
  • 难以确定预后因素是否直接影响萎缩。
  • 临床试验中的患者人群不一定代表真实世界患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: To summarize the rates of atrophy, risk factors, and atrophy-associated visual outcomes in patients with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (VEGF) treatment for macular neovascularization (MNV). CLINICAL RELEVANCE: Age-related macular degeneration is a leading cause of vision loss worldwide, and VEGF inhibitors are the primary treatment for nAMD. However, atrophy is observed frequently in eyes treated with anti-VEGF therapy, prompting questions regarding a causative role for these therapies in atrophy development. METHODS: PubMed was searched for articles published in the past 5 years (January 1, 2014, through January 10, 2019). Studies including atrophy outcome(s) in patients with age-related macular degeneration who received anti-VEGF treatment were included. Review articles, retrospective studies, case reports or studies, preclinical studies, prevalence data reports, and non-English studies were excluded. Randomization was not required. RESULTS: Overall, 145 studies were identified; 29 publications were included, with cohorts ranging from 8 to 1185 eyes. Imaging methods used to assess atrophy varied across studies. All studies confirmed the occurrence of atrophy, and when available, longitudinal data from the included studies demonstrated an increase in atrophy incidence over time. Key risk factors or phenotypes associated with atrophy were fellow eye atrophy, reticular pseudodrusen, increased injections, and type 3 lesion. In addition, visual acuity loss was noted with foveal atrophy. DISCUSSION: All studies demonstrated that atrophy occurs in the context of MNV treated with anti-VEGF therapy; however, it is not clear whether anti-VEGF treatment is causative of atrophy versus being associated with atrophy development. The included studies were not designed or powered to assess atrophy as a primary outcome. In addition, it is difficult to determine whether prognostic factors directly affect atrophy. Furthermore, patient populations in clinical trials do not necessarily represent real-world patients. Although phenotypes and risk factors may help to identify those at greater risk of atrophy developing, it is important to recognize that adequately treating exudative MNV remains the best option to optimize vision outcomes in patients with nAMD, particularly given the risk of vision loss with undertreatment observed in the real world.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Sadda SR, Guymer R, Monés JM, et al. Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion. Ophthalmology. 2019. PMID: 32081493. doi:10.1016/j.ophtha.2019.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。